Samuel Backenroth - 31 Mar 2023 Form 4 Insider Report for Vascular Biogenics Ltd.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 31 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Apr 2023, 16:36:39 UTC
Prior SEC filing: 03 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Samuel Backenroth

Key filing fact

Samuel Backenroth filed Form 4 for Vascular Biogenics Ltd. on 18 Apr 2023.

Key facts

This page summarizes Samuel Backenroth's Form 4 filing for Vascular Biogenics Ltd..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Apr 2023, 16:36.

Change

Previous filing in this sequence was filed on 03 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VBLT transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +525,000
Change %
Price
Shares after: 525,000
Date: 31 Mar 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VBLT transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -525,000
Change %: -75%
Price: $0.000000
Shares after: 175,000
Date: 31 Mar 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 525,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the vesting and settlement of a portion of restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents a contingent right to receive one Ordinary Share, par value NIS 0.01, with an exercise price of NIS 0.01 per Ordinary Share.

Footnote F2

75% of the RSUs vested on March 31, 2023, with the remaining 25% vesting on August 9, 2024. The RSUs have no expiration date and have an exercise price of NIS 0.01 per Ordinary Share.